98480-31-0

Basic information

• Product Name: [1-(4-BROMO-PHENYL)-CYCLOPROPYL]-METHANOL
• Synonyms: [1-(4-BROMO-PHENYL)-CYCLOPROPYL]-METHANOL;1-(4-BroMophenyl)-1-cyclopropaneMethanol;1-(p-BroMophenyl)cyclopropaneMethanol
• CAS NO: 98480-31-0
• Molecular Formula: C₁₀H₁₁BrO
• Molecular Weight: 227.09774
• Product Categories: Aromatics;Inhibitors
• Mol File: 98480-31-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Room temperature.
• CAS DataBase Reference: [1-(4-BROMO-PHENYL)-CYCLOPROPYL]-METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: [1-(4-BROMO-PHENYL)-CYCLOPROPYL]-METHANOL(98480-31-0)
• EPA Substance Registry System: [1-(4-BROMO-PHENYL)-CYCLOPROPYL]-METHANOL(98480-31-0)

Safety Data

• Hazardous Substances Data: 98480-31-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
[1-(4-BROMO-PHENYL)-CYCLOPROPYL]-METHANOL is used as a key intermediate in the synthesis of amino acid derivatives, specifically as cathepsin cysteine protease inhibitors. These inhibitors play a crucial role in the development of therapeutic agents targeting various diseases, including cancer and neurodegenerative disorders. [1-(4-BROMO-PHENYL)-CYCLOPROPYL]-METHANOL's unique structure allows for the formation of potent and selective inhibitors, making it a valuable asset in drug discovery and development processes.

Upstream product

• 345965-52-8 1-(4-bromophenyl)cyclopropanecarboxylic acid 
• 16532-79-9 4-Bromophenylacetonitrile 
• 124276-67-1 1-(4-bromophenyl)cyclopropanecarbonitrile 
• 6120-95-2 1-phenyl-1-cyclopropane carboxylic acid 
• 638220-35-6 1-(4-bromophenyl)-cyclopropanecarboxylic acid methyl ester 

Downstream Products

• 1219741-77-1 methyl 5-[(6-chloro-5-{4-[1-(hydroxymethyl)cyclopropyl]phenyl}-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-benzimidazol-2-yl)oxy]-2-methylbenzoate 
• 1426925-13-4 1-(4-(2-chloro-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxylmethyl)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)cyclopropanecarbaldehyde O-methyl oxime 
• 1147531-61-0 1-(4-bromophenyl)cyclopropane-1-carbaldehyde 
• 1426925-14-5 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropane carbaldehyde 
• 1426925-15-6 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-(1-formyl cyclopropyl)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1426925-16-7 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-((4-(1-(methoxyimino)methyl)cyclopropyl)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1282659-26-0 [1-(4-bromophenyl)cyclopropyl]acetonitrile 
• 1620074-29-4 C₁₂H₁₃BrO₂ 
• 1620074-30-7 C₁₂H₁₅NO₂ 
• 1620074-31-8 C₁₂H₁₃IO₂ 
• 1620074-34-1 C₁₈H₂₅BO₄ 
• 1620074-35-2 C₃₁H₃₀N₂O₅ 
• 1620069-68-2 C₃₀H₂₈N₂O₅ 
• 1220219-36-2 (1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropyl)methanol 

Relevant articles and documents

Electrophilic Bromolactonization of Cyclopropyl Diesters Using Lewis Basic Chalcogenide Catalysts

An efficient and regioselective electrophilic bromolactonization of cyclopropylmethyl diesters using triphenylphosphine sulfide (Ph3PS) or diphenyl selenide (Ph2Se) as the Lewis basic chalcogenide catalyst has been developed. It was observed that Ph3PS favored the formation of anti-diastereomer and yielded the multi-functional γ-lactones. Interestingly, the diastereoselectivity was reversed when using Ph2Se as a catalyst where the syn-product instead of the anti-product was favored. (Figure presented.).

NOVEL SGLT INHIBITORS

The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synt

SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY

The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

NOVEL SGLT INHIBITORS

The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the sy

NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, Metabolic Syndrome, obesity, hypercholesterolemia, and hypertension

CATHEPSIN CYSTEINE PROTEASE INHIBITORS

This invention relates to a novel class of compounds, represented by the formula below, wherein the meanings of G, E, E, n, R1, R2, R3 et R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.